Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
553 hedge funds and large institutions have $22.5B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2023 Q1 according to their latest regulatory filings, with 80 funds opening new positions, 180 increasing their positions, 217 reducing their positions, and 130 closing their positions.
20% more funds holding in top 10
Funds holding in top 10: 69 → 83 (+14)
5% less capital invested
Capital invested by funds: $23.7B → $22.5B (-$1.2B)
10% less funds holding
Funds holding: 615 → 553 (-62)
17% less repeat investments, than reductions
Existing positions increased: 180 | Existing positions reduced: 217
38% less first-time investments, than exits
New positions opened: 80 | Existing positions closed: 130
69% less call options, than puts
Call options by funds: $278M | Put options by funds: $893M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$300M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$283M |
| 3 |
D.E. Shaw & Co
New York
|
+$237M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$223M |
| 5 |
DKCM
Davidson Kempner Capital Management
New York
|
+$213M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$851M |
| 2 |
JP Morgan Chase
New York
|
-$637M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$323M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$244M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$196M |
HZNP Hedge Fund Activity: Q1 2023 in Review
553 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q1 2023, worth a combined $22.5B — down 5.1% from $23.7B a quarter earlier.
Sellers outnumbered buyers: 130 funds closed out of HZNP and 80 opened new positions — a net loss of 50 holders — while 217 trimmed existing stakes and 180 added.
The largest buyer was Citadel Advisors, adding an estimated $300M. The largest seller was Capital International Investors, cutting an estimated $851M.
- 553 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q1 2023, down from 615 in Q4 2022.
- Funds reported $22.5B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q1 2023, down 5.1% quarter-over-quarter.
- 80 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q1 2023 and 130 closed out, a net change of -50 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q1 2023 was Citadel Advisors, an estimated $300M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q1 2023 was Capital International Investors, an estimated $851M sold.
Based on aggregated 13F filings for Q1 2023.